{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:05:36Z","timestamp":1789506336592,"version":"build-2803163510"},"reference-count":153,"publisher":"Elsevier","isbn-type":[{"value":"9780443313967","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.enz.2025.06.005","type":"book-chapter","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T19:41:26Z","timestamp":1753299686000},"page":"59-91","source":"Crossref","is-referenced-by-count":2,"title":["Computational approaches for designing viral protease inhibitors"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.enz.2025.06.005_bib0001","series-title":"Structure and Physics of Viruses. An Integrated Guide","first-page":"1","author":"Mateu","year":"2024"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.005_bib0002","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/molecules28030938","article-title":"Quercetin: a functional food-flavonoid incredibly attenuates emerging and re-emerging viral infections through immunomodulatory actions","volume":"28","author":"Shorobi","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/bs.enz.2025.06.005_bib0003","series-title":"Antiviral Drugs: From Basic Discovery Through Clinical Trials","first-page":"1","author":"Kazmierski","year":"2011"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.005_bib0004","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/v16030366","article-title":"Recent advances on targeting proteases for antiviral development","volume":"16","author":"Borges","year":"2024","journal-title":"Viruses"},{"issue":"26","key":"10.1016\/bs.enz.2025.06.005_bib0005","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.2174\/1568026623666221019110334","article-title":"Computational approaches in the discovery and development of therapeutic and prophylactic agents for viral diseases","volume":"22","author":"Gaurav","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.005_bib0006","series-title":"Viral Replication Enzymes and their Inhibitors Part B","first-page":"301","article-title":"Viral proteases: Structure, mechanism and inhibition","author":"Zephyr","year":"2021"},{"key":"10.1016\/bs.enz.2025.06.005_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1550158","article-title":"New strategies to enhance the efficiency and precision of drug discovery","volume":"16","author":"An","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/bs.enz.2025.06.005_bib0008","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3390\/ph16091259","article-title":"Revolutionizing medicinal chemistry: the application of artificial intelligence (AI) in early drug discovery","volume":"16","author":"Han","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"10.1016\/bs.enz.2025.06.005_bib0009","doi-asserted-by":"crossref","first-page":"12132","DOI":"10.1021\/acsomega.8b01683","article-title":"Drug resistance mutation L76V alters nonpolar interactions at the flap-core interface of HIV-1 Protease","volume":"3","author":"Wong-Sam","year":"2018","journal-title":"ACS Omega"},{"issue":"16","key":"10.1016\/bs.enz.2025.06.005_bib0010","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.bmcl.2019.03.037","article-title":"Discovery of the pan-genotypic hepatitis C virus NS3\/4A protease inhibitor voxilaprevir (GS-9857): a component of Vosevi\u00ae","volume":"29","author":"Taylor","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0011","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s42003-023-05071-y","article-title":"Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants","volume":"6","author":"Lin","year":"2023","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0012","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/bs.enz.2025.06.005_bib0013","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.str.2018.02.005","article-title":"Structural insights into the inhibition of Zika Virus NS2B-NS3 Protease by a Small-Molecule Inhibitor","volume":"26","author":"Li","year":"2018","journal-title":"Structure"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0014","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1128\/JVI.06225-11","article-title":"Ligand-bound structures of the dengue virus protease reveal the active conformation","volume":"86","author":"Noble","year":"2012","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/bs.enz.2025.06.005_bib0015","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1517\/17460441.2015.1083007","article-title":"Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities","volume":"10","author":"Huang","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/bs.enz.2025.06.005_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.775513","article-title":"Accurate Prediction of Inhibitor Binding to HIV-1 Protease Using CANDOCK","volume":"9","author":"Falls","year":"2022","journal-title":"Front Chem"},{"issue":"12","key":"10.1016\/bs.enz.2025.06.005_bib0017","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3390\/biom11121805","article-title":"Towards the De Novo Design of HIV-1 Protease Inhibitors Based on Natural Products","volume":"11","author":"Ch\u00e1vez-Hern\u00e1ndez","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-88388-4","article-title":"Identification of potential SARS-CoV-2 inhibitors among well-tolerated drugs using drug repurposing and in vitro approaches","volume":"15","author":"Oru\u00e7o\u011flu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.enz.2025.06.005_bib0019","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3762\/bjoc.12.267","article-title":"Computational methods in drug discovery","volume":"12","author":"Leelananda","year":"2016","journal-title":"Beilstein J. Org. Chem."},{"issue":"9","key":"10.1016\/bs.enz.2025.06.005_bib0020","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1023\/B:JCAM.0000005748.19093.e8","article-title":"Inhibition and substrate recognition\u2013a computational approach applied to HIV protease","volume":"17","author":"Vinkers","year":"2003","journal-title":"J Comput Aided Mol Des"},{"issue":"21","key":"10.1016\/bs.enz.2025.06.005_bib0021","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1021\/jm00047a001","article-title":"L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor","volume":"37","author":"Dorsey","year":"1994","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/bs.enz.2025.06.005_bib0022","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1021\/jm9602571","article-title":"Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2\/P2\u2032 structure-activity relationship, and molecular recognition of cyclic ureas","volume":"39","author":"Lam","year":"1996","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/bs.enz.2025.06.005_bib0023","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1006\/bbrc.2000.2139","article-title":"Computational design of new cyclic urea inhibitors for improved binding of HIV-1 aspartic protease","volume":"268","author":"Kotamarthi","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/bs.enz.2025.06.005_bib0024","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1021\/ci100200u","article-title":"Computational analysis of HIV-1 protease protein binding pockets","volume":"50","author":"Ko","year":"2010","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"10.1016\/bs.enz.2025.06.005_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019268","article-title":"Strength of hydrogen bond network takes crucial roles in the dissociation process of inhibitors from the HIV-1 protease binding pocket","volume":"6","author":"Li","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.005_bib0026","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1208\/s12248-014-9604-9","article-title":"Anti-HIV drug development through computational methods","volume":"16","author":"Gu","year":"2014","journal-title":"AAPS J."},{"issue":"12","key":"10.1016\/bs.enz.2025.06.005_bib0027","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.str.2009.10.008","article-title":"Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance","volume":"17","author":"Chaudhury","year":"2009","journal-title":"Structure"},{"issue":"7","key":"10.1016\/bs.enz.2025.06.005_bib0028","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.tim.2016.03.010","article-title":"Improving viral protease inhibitors to counter drug resistance","volume":"24","author":"Kurt Yilmaz","year":"2016","journal-title":"Trends Microbiol."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0029","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/ar7001232","article-title":"Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance","volume":"41","author":"Ghosh","year":"2008","journal-title":"Acc. Chem. Res."},{"issue":"12","key":"10.1016\/bs.enz.2025.06.005_bib0030","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nrd1907","volume":"4","author":"Flexner","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"24","key":"10.1016\/bs.enz.2025.06.005_bib0031","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1016\/j.bmc.2007.09.010","article-title":"Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV","volume":"15","author":"Ghosh","year":"2007","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/bs.enz.2025.06.005_bib0032","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/COH.0b013e3283136cee","article-title":"New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors","volume":"3","author":"Nalam","year":"2008","journal-title":"Curr Opin HIV AIDS"},{"issue":"11","key":"10.1016\/bs.enz.2025.06.005_bib0033","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1021\/cb400468c","article-title":"Testing the substrate-envelope hypothesis with designed pairs of compounds","volume":"8","author":"Shen","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"15","key":"10.1016\/bs.enz.2025.06.005_bib0034","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1021\/jm5008352","article-title":"An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases","volume":"57","author":"Ung","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0035","first-page":"6","article-title":"Anti-HIV proteinase monoclonal antibody F11.2.32 that inhibits enzyme activity","volume":"17","author":"Stouracova","year":"1998","journal-title":"Gen. Physiol. Biophys."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0036","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/s41598-020-62423-y","article-title":"Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations","volume":"10","author":"Badaya","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0037","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1110\/ps.062501507","article-title":"Efficient molecular docking of NMR structures: application to HIV-1 protease","volume":"16","author":"Huang","year":"2007","journal-title":"Protein Sci."},{"issue":"3","key":"10.1016\/bs.enz.2025.06.005_bib0038","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1021\/ci700044s","article-title":"Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries","volume":"47","author":"Chang","year":"2007","journal-title":"J. Chem. Inf. Model"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.005_bib0039","first-page":"785","article-title":"Effect of biomolecular conformation on docking simulation: a case study on a potent HIV-1 protease inhibitor","volume":"14","author":"Razzaghi-Asl","year":"2015","journal-title":"Iran J Pharm Res"},{"issue":"5","key":"10.1016\/bs.enz.2025.06.005_bib0040","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/acs.jcim.5b00667","article-title":"Computational prediction of HIV-1 resistance to protease inhibitors","volume":"56","author":"Hosseini","year":"2016","journal-title":"J. Chem. Inf. Model."},{"issue":"11","key":"10.1016\/bs.enz.2025.06.005_bib0041","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/molecules23112751","article-title":"A computational approach for the prediction of HIV resistance based on amino acid and nucleotide descriptors","volume":"23","author":"Tarasova","year":"2018","journal-title":"Molecules"},{"issue":"46","key":"10.1016\/bs.enz.2025.06.005_bib0042","doi-asserted-by":"crossref","first-page":"17355","DOI":"10.1073\/pnas.0607274103","article-title":"Genotypic predictors of human immunodeficiency virus type 1 drug resistance","volume":"103","author":"Rhee","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"13","key":"10.1016\/bs.enz.2025.06.005_bib0043","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1093\/nar\/gkg575","article-title":"Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes","volume":"31","author":"Beerenwinkel","year":"2003","journal-title":"Nucleic. Acids. Res."},{"issue":"12","key":"10.1016\/bs.enz.2025.06.005_bib0044","doi-asserted-by":"crossref","first-page":"8271","DOI":"10.1073\/pnas.112177799","article-title":"Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype","volume":"99","author":"Beerenwinkel","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"20","key":"10.1016\/bs.enz.2025.06.005_bib0045","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1021\/acs.jcim.4c01037","article-title":"Improving predictive efficacy for drug resistance in novel HIV-1 protease inhibitors through transfer learning mechanisms","volume":"64","author":"Tunc","year":"2024","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"10.1016\/bs.enz.2025.06.005_bib0046","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11596340-000000000-00000","article-title":"Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial","volume":"11","author":"Elgadi","year":"2011","journal-title":"Drugs R. D."},{"issue":"17","key":"10.1016\/bs.enz.2025.06.005_bib0047","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?","volume":"23","author":"Loos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/bs.enz.2025.06.005_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012149","article-title":"Discovery of novel HIV protease inhibitors using modern computational techniques","volume":"23","author":"Okafor","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/bs.enz.2025.06.005_bib0049","first-page":"209","article-title":"Identification of novel lead to inhibit HIV protease: a computational approach","volume":"12","author":"Soujanya","year":"2023","journal-title":"Bull. Env. Pharmacol. Life Sci."},{"issue":"5","key":"10.1016\/bs.enz.2025.06.005_bib0050","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/biom13050858","article-title":"AI-aided search for new HIV-1 protease ligands","volume":"13","author":"Arrigoni","year":"2023","journal-title":"Biomolecules"},{"issue":"42","key":"10.1016\/bs.enz.2025.06.005_bib0051","doi-asserted-by":"crossref","first-page":"26748","DOI":"10.1039\/D4CP02895C","article-title":"Quantum mechanical analysis of newly synthesized HIV-1 protease inhibitors: evaluation of wild-type and resistant strain binding interactions","volume":"26","author":"Silva","year":"2024","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"5","key":"10.1016\/bs.enz.2025.06.005_bib0052","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1021\/acsbiomedchemau.4c00040","article-title":"Design, synthesis, and biological evaluation of darunavir analogs as HIV-1 protease inhibitors","volume":"4","author":"Ur Rehman","year":"2024","journal-title":"ACS Bio Med Chem Au"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0053","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1038\/s41598-024-53940-1","article-title":"FMO-guided design of darunavir analogs as HIV-1 protease inhibitors","volume":"14","author":"Chuntakaruk","year":"2024","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/bs.enz.2025.06.005_bib0054","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/jcc.27298","article-title":"Machine learning-guided design of potent darunavir analogs targeting HIV-1 proteases: a computational approach for antiretroviral drug discovery","volume":"45","author":"Chuntakaruk","year":"2024","journal-title":"J. Comput. Chem."},{"key":"10.1016\/bs.enz.2025.06.005_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1541942","article-title":"AI in HIV research: advances and future directions","volume":"16","author":"Jin","year":"2025","journal-title":"Front Microbiol."},{"issue":"2","key":"10.1016\/bs.enz.2025.06.005_bib0056","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s13337-021-00697-0","article-title":"Current therapeutics against HCV","volume":"32","author":"Bhattacharjee","year":"2021","journal-title":"Virusdisease"},{"issue":"11","key":"10.1016\/bs.enz.2025.06.005_bib0057","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from punjab, india: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0058","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/ar700109k","article-title":"Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection","volume":"41","author":"Njoroge","year":"2008","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0059","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/bs.enz.2025.06.005_bib0060","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nbt.2020","article-title":"Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus","volume":"29","author":"Kwong","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/bs.enz.2025.06.005_bib0061","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00726-023-03286-1","article-title":"Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories","volume":"55","author":"Feral","year":"2023","journal-title":"Amino Acids"},{"issue":"30","key":"10.1016\/bs.enz.2025.06.005_bib0062","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/bs.enz.2025.06.005_bib0063","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/ct600151y","article-title":"Computational study of the effects of mutations A156T, D168V, and D168Q on the binding of HCV protease inhibitors","volume":"2","author":"Guo","year":"2006","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/bs.enz.2025.06.005_bib0064","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2147\/IDR.S218584","article-title":"Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide","volume":"12","author":"Wu","year":"2019","journal-title":"Infect. Drug Resist."},{"issue":"28","key":"10.1016\/bs.enz.2025.06.005_bib0065","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1021\/acs.jpcb.7b04562","article-title":"Exploring the drug resistance of HCV protease","volume":"121","author":"Jindal","year":"2017","journal-title":"J. Phys. Chem. B"},{"issue":"2","key":"10.1016\/bs.enz.2025.06.005_bib0066","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/bab.1479","article-title":"Computational study on the drug resistance mechanism of HCV NS3 protease to BMS-605339","volume":"64","author":"Wang","year":"2017","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/bs.enz.2025.06.005_bib0067","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1139\/bcb-2014-0039","article-title":"Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3\/4A protease","volume":"92","author":"Wang","year":"2014","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/bs.enz.2025.06.005_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2019.107154","article-title":"Understanding of the drug resistance mechanism of hepatitis C virus NS3\/4A to paritaprevir due to D168N\/Y mutations: a molecular dynamics simulation perspective","volume":"83","author":"Boonma","year":"2019","journal-title":"Comput. Biol. Chem."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0069","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/molecules29010225","article-title":"Computer-aided prediction of the interactions of viral proteases with antiviral drugs: antiviral potential of broad-spectrum drugs","volume":"29","author":"Ren","year":"2023","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.005_bib0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cld.332","article-title":"Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment","volume":"3","author":"Lin","year":"2014","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"5","key":"10.1016\/bs.enz.2025.06.005_bib0071","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/17474124.2015.1032938","article-title":"Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy","volume":"9","author":"Brayer","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/bs.enz.2025.06.005_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167503","article-title":"Deciphering the molecular mechanism of HCV protease inhibitor fluorination as a general approach to avoid drug resistance","volume":"434","author":"Zephyr","year":"2022","journal-title":"J. Mol. Biol."},{"issue":"20","key":"10.1016\/bs.enz.2025.06.005_bib0073","first-page":"8270","article-title":"Development of glecaprevir: conformations, crystal structures, and efficient solid\u2013solid conversion for a highly polymorphic macrocyclic drug","volume":"24","author":"Chen","year":"2024","journal-title":"Cryst. Growth Des."},{"issue":"16","key":"10.1016\/bs.enz.2025.06.005_bib0074","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.bmcl.2019.03.037","article-title":"Discovery of the pan-genotypic hepatitis C virus NS3\/4A protease inhibitor voxilaprevir (GS-9857): a component of Vosevi\u00ae","volume":"29","author":"Taylor","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/bs.enz.2025.06.005_bib0075","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/v16081250","article-title":"Pharmacophore-assisted covalent docking identifies a potential covalent inhibitor for drug-Resistant genotype 3 variants of hepatitis c viral NS3\/4A serine protease","volume":"16","author":"Iman","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.005_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142087","article-title":"Design and synthesis of new HCV NS3\/4A protease inhibitors to effective against drug resistance","volume":"1336","author":"Oksuz","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/bs.enz.2025.06.005_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2024.108936","article-title":"On the steroids extracted from soft corals against the NS3\/4A protease of hepatitis C virus","volume":"136","author":"Nguyen","year":"2025","journal-title":"J Mol Graph Model"},{"issue":"6","key":"10.1016\/bs.enz.2025.06.005_bib0078","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.3390\/ijms26062680","article-title":"Enhancing HCV NS3 inhibitor classification with optimized molecular fingerprints using random forest","volume":"26","author":"Atasever","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0079","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.1038\/s41598-024-59933-4","article-title":"HBCVTr: an end-to-end transformer with a deep neural network hybrid model for anti-HBV and HCV activity predictor from SMILES","volume":"14","author":"Meewan","year":"2024","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/bs.enz.2025.06.005_bib0080","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.3390\/ijms20143572","article-title":"Targeting HIV\/HCV coinfection using a machine learning-based multiple quantitative structure-activity relationships (Multiple QSAR) method","volume":"20","author":"Wei","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/bs.enz.2025.06.005_bib0081","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V'kovski","year":"2021","journal-title":"Nat. Rev. Micro."},{"issue":"18","key":"10.1016\/bs.enz.2025.06.005_bib0082","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/bs.enz.2025.06.005_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2025.107687","article-title":"Advances in COVID-19 therapeutics: Exploring the role of lectins and protease inhibitors","volume":"205","author":"Pita Dos Santos","year":"2025","journal-title":"Microb. Pathog."},{"issue":"9","key":"10.1016\/bs.enz.2025.06.005_bib0084","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/jmv.25768","article-title":"A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV)","volume":"92","author":"Dong","year":"2020","journal-title":"J. Med. Virol."},{"issue":"7811","key":"10.1016\/bs.enz.2025.06.005_bib0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"7835","key":"10.1016\/bs.enz.2025.06.005_bib0086","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"issue":"18","key":"10.1016\/bs.enz.2025.06.005_bib0087","doi-asserted-by":"crossref","first-page":"26775","DOI":"10.1007\/s11356-021-17642-9","article-title":"In-silico screening of naturally derived phytochemicals against SARS-CoV Main protease","volume":"29","author":"Mostafa","year":"2022","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"10.1016\/bs.enz.2025.06.005_bib0088","doi-asserted-by":"crossref","first-page":"246","DOI":"10.12688\/f1000research.143633.3","article-title":"Identification of compounds from natural Peruvian sources as potential inhibitors of SARS-CoV-2 Mpro mutations by virtual screening and computational simulations","volume":"13","author":"Barazorda-Ccahuana","year":"2024","journal-title":"F1000Res"},{"key":"10.1016\/bs.enz.2025.06.005_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108953","article-title":"On the dual role of (+)-catechin as primary antioxidant and inhibitor of viral proteases","volume":"180","author":"Ciardullo","year":"2024","journal-title":"Comput. Biol. Med."},{"issue":"7","key":"10.1016\/bs.enz.2025.06.005_bib0090","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/biom14070755","article-title":"In silico comparative analysis of ivermectin and nirmatrelvir inhibitors interacting with the SARS-CoV-2 main protease","volume":"14","author":"de Oliveira S\u00f3","year":"2024","journal-title":"Biomolecules."},{"key":"10.1016\/bs.enz.2025.06.005_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150763","article-title":"Famotidine increases cellular phospho-tyrosine levels","volume":"734","author":"Zubiete-Franco","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/bs.enz.2025.06.005_bib0092","doi-asserted-by":"crossref","DOI":"10.1002\/open.202400091","article-title":"SARS-CoV-2 PLpro inhibition: evaluating in silico repurposed fidaxomicin\u2019s antiviral activity through in vitro assessment","volume":"13","author":"Proti\u0107","year":"2024","journal-title":"ChemistryOpen."},{"issue":"9","key":"10.1016\/bs.enz.2025.06.005_bib0093","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jiph.2020.06.016","article-title":"In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing","volume":"13","author":"Kumar","year":"2020","journal-title":"J Infect Public Health"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0094","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-88388-4","article-title":"Identification of potential SARS-CoV-2 inhibitors among well-tolerated drugs using drug repurposing and in vitro approaches","volume":"15","author":"Oru\u00e7o\u011flu","year":"2025","journal-title":"Sci. Rep."},{"issue":"21","key":"10.1016\/bs.enz.2025.06.005_bib0095","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.3390\/molecules25215172","article-title":"Drugs repurposing using QSAR, docking and molecular dynamics for possible inhibitors of the SARS-CoV-2 Mpro protease","volume":"25","author":"Tejera","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/bs.enz.2025.06.005_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117627","article-title":"Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease","volume":"251","author":"Kandeel","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0097","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77700-z","article-title":"Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir","volume":"10","author":"Bolcato","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.enz.2025.06.005_bib0098","article-title":"Computational evaluation of the inhibition efficacies of HIV antivirals on SARS-CoV-2 (COVID-19) protease and Identification of 3D pharmacophore and hit compounds","volume":"2020","author":"Raphael","year":"2020","journal-title":"Adv Pharmacol Pharm Sci"},{"issue":"6","key":"10.1016\/bs.enz.2025.06.005_bib0099","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269563","article-title":"Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening","volume":"17","author":"Sanachai","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/bs.enz.2025.06.005_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.105183","article-title":"Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery","volume":"142","author":"Ray","year":"2022","journal-title":"Comput. Biol. Med."},{"issue":"8","key":"10.1016\/bs.enz.2025.06.005_bib0101","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1080\/07391102.2020.1848636","article-title":"Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors","volume":"40","author":"Uniyal","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"2","key":"10.1016\/bs.enz.2025.06.005_bib0102","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202100062","article-title":"Screening of clinically approved and investigation drugs as potential inhibitors of SARS-CoV-2: a combined in silico and in\u2005vitro study","volume":"41","author":"Durdagi","year":"2022","journal-title":"Mol Inform"},{"key":"10.1016\/bs.enz.2025.06.005_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131920","article-title":"Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors","volume":"1250","author":"Uddin","year":"2022","journal-title":"J. Mol. Struct."},{"issue":"6","key":"10.1016\/bs.enz.2025.06.005_bib0104","doi-asserted-by":"crossref","DOI":"10.1177\/13596535241305536","article-title":"Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach","volume":"29","author":"Metwaly","year":"2024","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/bs.enz.2025.06.005_bib0105","article-title":"Computational assessment of clinical drugs against SARS-CoV-2: foreseeing molecular mechanisms and potent Mpro inhibitors","volume":"26","author":"Panda","year":"2025","journal-title":"ChemPhysChem"},{"issue":"11","key":"10.1016\/bs.enz.2025.06.005_bib0106","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400253","article-title":"Synthesis, in vitro and in silico evaluation of gallamide and selenogallamide derivatives as inhibitors of the SARS-CoV-2 main protease","volume":"357","author":"Carvalho","year":"2024","journal-title":"Arch Pharm (Weinheim)"},{"issue":"Pt 4","key":"10.1016\/bs.enz.2025.06.005_bib0107","article-title":"Disrupting protease and deubiquitinase activities of SARS-CoV-2 papain-like protease by natural and synthetic products discovered through multiple computational and biochemical approaches","volume":"277","author":"Waqas","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"12","key":"10.1016\/bs.enz.2025.06.005_bib0108","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202401697","article-title":"Synthesis, biological evaluation and molecular docking studies of new thiazolidinone derivatives as NNRTIs and SARS-CoV-2 main protease inhibitors","volume":"21","author":"Fesatidou","year":"2024","journal-title":"Chem. Biodivers."},{"issue":"2","key":"10.1016\/bs.enz.2025.06.005_bib0109","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/med.21862","article-title":"Haste makes waste: a critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition","volume":"42","author":"Macip","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/bs.enz.2025.06.005_bib0110","article-title":"Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review","volume":"12","author":"Mukae","year":"2025","journal-title":"Ther Adv Infect Dis"},{"issue":"2","key":"10.1016\/bs.enz.2025.06.005_bib0111","article-title":"En nombre del grupo de estudio COVID CODE SPAIN. Effectiveness and safety of remdesivir and nirmatrelvir-ritonavir in mild to moderate COVID-19 in spanish hospital emergency departments","volume":"165","author":"Rodr\u00edguez-Leal","year":"2025","journal-title":"Med. Clin. (Barc)"},{"issue":"25","key":"10.1016\/bs.enz.2025.06.005_bib0112","doi-asserted-by":"crossref","first-page":"00077","DOI":"10.1016\/j.jmii.2024.11.014","article-title":"Effectiveness of molnupiravir as early treatment for COVID-19 to prevent mortality and hospitalisation in high-risk adults: a systematic review and meta-analysis of randomised trials and real-world studies involving 1,612,082 patients","volume":"S1684-1182","author":"Lin","year":"2025","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0113","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/bs.enz.2025.06.005_bib0114","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1021\/acs.jpclett.4c03654","article-title":"A reflection on the use of molecular simulation to respond to SARS-CoV-2 pandemic threats","volume":"16","author":"Casalino","year":"2025","journal-title":"J. Phys. Chem. Lett."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0115","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12985-024-02607-4","article-title":"Targeting SARS-CoV-2 main protease: a comprehensive approach using advanced virtual screening, molecular dynamics, and in vitro validation","volume":"21","author":"Gevorgyan","year":"2024","journal-title":"Virol. J."},{"issue":"Pt 3","key":"10.1016\/bs.enz.2025.06.005_bib0116","article-title":"Enhancing the understandings on SARS-CoV-2 main protease (Mpro) mutants from molecular dynamics and machine learning","volume":"310","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"40","key":"10.1016\/bs.enz.2025.06.005_bib0117","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202409527","article-title":"Pomotrelvir and nirmatrelvir binding and reactivity with SARS-CoV-2 main protease: implications for resistance mechanisms from computations","volume":"63","author":"Schillings","year":"2024","journal-title":"Angew. Chem. Int. Ed Engl."},{"issue":"2","key":"10.1016\/bs.enz.2025.06.005_bib0118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0318712","article-title":"Evaluating the structure-based virtual screening performance of SARS-CoV-2 main protease: a benchmarking approach and a multistage screening example against the wild-type and Omicron variants","volume":"20","author":"Galal","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0119","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/bs.enz.2025.06.005_bib0120","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/07391102.2021.2024260","article-title":"Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system","volume":"41","author":"Komatsu","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0121","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-69021-2","article-title":"Generative artificial intelligence performs rudimentary structural biology modeling","volume":"14","author":"Ille","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.enz.2025.06.005_bib0122","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1418516","article-title":"Recent advances in the study of zika virus structure, drug targets, and inhibitors","volume":"15","author":"Feng","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/bs.enz.2025.06.005_bib0123","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1061937","article-title":"Assessing the potential of NS2B\/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach","volume":"13","author":"Norshidah","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"10.1016\/bs.enz.2025.06.005_bib0124","first-page":"288","article-title":"West Nile Virus (WNV): one-health and eco-health global risks","volume":"12","author":"Bruno","year":"2025","journal-title":"Vet Sci"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.005_bib0125","first-page":"434","article-title":"Yellow fever: global impact, epidemiology, pathogenesis, and integrated prevention approaches","volume":"32","author":"Srivastava","year":"2024","journal-title":"Infez. Med."},{"key":"10.1016\/bs.enz.2025.06.005_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2025.107397","article-title":"Molecular mechanisms of Japanese encephalitis virus infection and advances in vaccine research","volume":"201","author":"Gong","year":"2025","journal-title":"Microb. Pathog."},{"issue":"8","key":"10.1016\/bs.enz.2025.06.005_bib0127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010664","article-title":"Epidemiologic and environmental characterization of the Re-emergence of St. Louis Encephalitis Virus in California, 2015-2020","volume":"16","author":"Danforth","year":"2022","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/bs.enz.2025.06.005_bib0128","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105878","article-title":"Characterisation of ten NS2B-NS3 proteases: paving the way for pan-flavivirus drugs","volume":"226","author":"Voss","year":"2024","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0129","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/v14010044","article-title":"Potential role of flavivirus NS2B-NS3 proteases in viral pathogenesis and anti-flavivirus drug discovery employing animal cells and models: a review","volume":"14","author":"Wahaab","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.005_bib0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/pathogens11030293","article-title":"Antiviral agents against flavivirus protease: prospect and future direction","volume":"11","author":"Samrat","year":"2022","journal-title":"Pathogens"},{"issue":"16","key":"10.1016\/bs.enz.2025.06.005_bib0131","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/cmdc.202100246","article-title":"Ligand accessibility insights to the dengue virus NS3-NS2B protease assessed by long-timescale molecular dynamics simulations","volume":"16","author":"Kronenberger","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/bs.enz.2025.06.005_bib0132","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2024.1510029","article-title":"Machine learning and molecular docking prediction of potential inhibitors against dengue virus","volume":"12","author":"Hanson","year":"2024","journal-title":"Front Chem"},{"issue":"45","key":"10.1016\/bs.enz.2025.06.005_bib0133","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1021\/acs.jpcb.4c05388","article-title":"Machine-learning approach to identify potential dengue virus protease inhibitors: a computational perspective","volume":"128","author":"Abduljalil","year":"2024","journal-title":"J. Phys. Chem. B"},{"issue":"8","key":"10.1016\/bs.enz.2025.06.005_bib0134","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/1062936X.2024.2392677","article-title":"Predicting repurposed drugs targeting the NS3 protease of dengue virus using machine learning-based QSAR, molecular docking, and molecular dynamics simulations","volume":"35","author":"Chongjun","year":"2024","journal-title":"SAR QSAR Environ. Res."},{"issue":"43","key":"10.1016\/bs.enz.2025.06.005_bib0135","doi-asserted-by":"crossref","first-page":"27684","DOI":"10.1039\/D4CP02867H","article-title":"In silico validation of allosteric inhibitors targeting Zika virus NS2B-NS3 protease","volume":"26","author":"Wang","year":"2024","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/bs.enz.2025.06.005_bib0136","article-title":"Identification and evaluation of natural compounds as potential inhibitors of ns2b-ns3 zika virus protease: a computational approach","author":"Anede","year":"2024","journal-title":"Mol. Biotechnol."},{"issue":"Pt 1","key":"10.1016\/bs.enz.2025.06.005_bib0137","article-title":"Identification of novel and potential inhibitors against the dengue virus NS2B\/NS3 protease using virtual screening and biomolecular simulations","volume":"272","author":"Nasir","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/bs.enz.2025.06.005_bib0138","first-page":"631","article-title":"In silico screening of phytocompounds from west african traditional medicine and molecular docking targeting dengue virus protein NS2B\/NS3","volume":"316","author":"Kantagba","year":"2024","journal-title":"Stud. Health Technol. Inform."},{"key":"10.1016\/bs.enz.2025.06.005_bib0139","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1524951","article-title":"Paritaprevir as a pan-antiviral against different flaviviruses","volume":"12","author":"Yadav","year":"2025","journal-title":"Front Mol. Biosci."},{"issue":"2","key":"10.1016\/bs.enz.2025.06.005_bib0140","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/acs.jcim.3c01505","article-title":"Aminopyrimidine derivatives as multiflavivirus antiviral compounds identified from a consensus virtual screening approach","volume":"64","author":"Serafim","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/bs.enz.2025.06.005_bib0141","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105516","article-title":"Flavivirus proteases: the viral Achilles heel to prevent future pandemics","volume":"210","author":"Teramoto","year":"2023","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.enz.2025.06.005_bib0142","doi-asserted-by":"crossref","DOI":"10.1038\/s41579-025-01177-8","article-title":"Chikungunya virus and other emerging arthritogenic alphaviruses","author":"de Souza","year":"2025","journal-title":"Nat. Rev. Micro."},{"issue":"7","key":"10.1016\/bs.enz.2025.06.005_bib0143","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3390\/v13071307","article-title":"Antivirals against the Chikungunya Virus","volume":"13","author":"Battisti","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.005_bib0144","doi-asserted-by":"crossref","DOI":"10.1038\/srep17125","article-title":"Chikungunya nsP2 protease is not a papain-like cysteine protease and the catalytic dyad cysteine is interchangeable with a proximal serine","volume":"5","author":"Saisawang","year":"2015","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/bs.enz.2025.06.005_bib0145","doi-asserted-by":"crossref","first-page":"7382","DOI":"10.1128\/AAC.01421-16","article-title":"Design and Validation of Novel Chikungunya Virus Protease Inhibitors","volume":"60","author":"Das","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/bs.enz.2025.06.005_bib0146","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.01.002","article-title":"Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus","volume":"98","author":"Bassetto","year":"2013","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/bs.enz.2025.06.005_bib0147","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/1087057112460091","article-title":"A phenotypic assay to identify Chikungunya virus inhibitors targeting the nonstructural protein nsP2","volume":"18","author":"Lucas-Hourani","year":"2013","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/bs.enz.2025.06.005_bib0148","doi-asserted-by":"crossref","DOI":"10.1038\/srep20122","article-title":"Inhibition of chikungunya virus replication by 1-[(2-Methylbenzimidazol-1-yl) Methyl]-2-Oxo-Indolin-3-ylidene] Amino] Thiourea(MBZM-N-IBT)","volume":"6","author":"Mishra","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.enz.2025.06.005_bib0149","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejmech.2014.10.042","article-title":"Thiazolidone derivatives as inhibitors of chikungunya virus","volume":"89","author":"Jadav","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/bs.enz.2025.06.005_bib0150","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/cbdd.12621","article-title":"Discovery of novel peptidomimetics as irreversible CHIKV NsP2 protease inhibitors using quantum mechanical-based ligand descriptors","volume":"86","author":"El-labbad","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/bs.enz.2025.06.005_bib0151","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biochi.2018.04.004","article-title":"Chikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease","volume":"149","author":"Singh","year":"2018","journal-title":"Biochimie"},{"key":"10.1016\/bs.enz.2025.06.005_bib0152","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.virol.2020.05.010","article-title":"Evaluation of novobiocin and telmisartan for anti-CHIKV activity","volume":"548","author":"Tripathi","year":"2020","journal-title":"Virology"},{"key":"10.1016\/bs.enz.2025.06.005_bib0153","doi-asserted-by":"crossref","first-page":"85938","DOI":"10.1039\/C5RA14469H","article-title":"Reaching beyond HIV\/HCV: nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus","volume":"5","author":"Bhakat","year":"2015","journal-title":"RSC Adv."}],"container-title":["The Enzymes","Viral Proteases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:54:46Z","timestamp":1768938886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874604725000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443313967"],"references-count":153,"URL":"https:\/\/doi.org\/10.1016\/bs.enz.2025.06.005","relation":{},"ISSN":["1874-6047"],"issn-type":[{"value":"1874-6047","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}